The FDA has acknowledged receipt of Actavis's resubmitted New Drug Application for its investigational atypical antipsychotic, cariprazine, which is indicated for the treatment of patients with schizophrenia and manic or mixed episodes associated with bipolar I disorder.
Cognitive impairment in patients with bipolar disorder is a growing research priority. Long suspected to be restricted to those with symptomatic illness, cognitive impairment has also been found in patients who are well controlled and euthymic.
Bipolar patients are among the most difficult to treat, in part because mania is alluring and in part because they are often poor historians. As with any patient who must take medication for a chronic condition, bipolar patients' adherence rates generally decline over time. About two-thirds of bipolar patients take more than 1 medication for this condition, and an antidepressant is often one component of the drug regimen.
Patients with bipolar disorder and other mental illnesses are more likely to be tested for human immunodeficiency virus.
Up to 60% of patients diagnosed with bipolar disorder cause harm to themselves at least once throughout their lifetimes, and at least 5% of them commit suicide. Nevertheless, few prospective studies have examined self-harm in BPD patients specifically.
Primary care that includes mental health screenings and treatments that take into account a patient's language and cultural background can help address mental health care disparities among ethnic minorities.
Vitamin D may have a regulative role in seasonal affective disorder development.
Patients with bipolar disorder who are treated with lithium have a higher risk for long-lasting kidney damage and thus require rigorous monitoring.
Based on patient response rates and efficacy, olanzapine/fluoxetine is the ideal first-line treatment for depression caused by bipolar disorder.
Medications might confer only marginal benefit for cognitive deficits in bipolar disorder.
Actavis's supplemental New Drug Application for asenapine to treat manic or mixed episodes related to bipolar disorder in pediatric patients has been accepted by the FDA and given priority review status.
The broad range of skills pharmacists possess can improve medication adherence and antipsychotic polypharmacy among patients with mental disorders
Medication nonadherence is often disastrous for bipolar patients, as it can lead to poor impulse control, increased risk of hospitalization, and even suicide.
While the etiology and pathophysiology of seasonal affective disorder are not clearly understood, there may be several underlying factors that lead to its presentation.
Adults aged 50 years or older who feel comfortable about aging are more likely to seek preventive health care services.
The effective management of psychotic disorders in our society requires a focused multidisciplinary approach.
Eating the recommended 5 servings of fruits and vegetables each day is associated with high mental well-being.
New report outlines suicide risks and prevention strategies to address high global suicide rates.
A recent study examines the effects of delayed diagnosis on the treatment outcomes of bipolar patients with bipolar disorder.
A serious, chronic mental disease, bipolar disorder is treatable, and therapeutic options are increasing.
Prone to comorbidities, patients with bipolar disorder can benefit from collaborative care among health care providers.
Researchers review evidence pointing to catecholaminergic"cholinergic imbalance as the factor that influences cycling between affective states.
Patients and clinicians can work together to determine appropriate and personally tailored self-management interventions.
